We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-2.98%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.33B
AUM Growth
-$428M
Cap. Flow
-$106M
Cap. Flow %
-2.44%
Top 10 Hldgs %
30.21%
Holding
157
New
4
Increased
80
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$22.8M
2
XLO icon
Xilio Therapeutics
XLO
+$20.3M
3
AURA icon
Aura Biosciences
AURA
+$18M
4
CMPX icon
Compass Therapeutics
CMPX
+$17.7M
5
AGL icon
Agilon Health
AGL
+$10.2M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$49M
2
ALLK
Allakos
ALLK
+$32.4M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$26.3M
4
BOLT icon
Bolt Biotherapeutics
BOLT
+$20.9M
5
OSH
Oak Street Health, Inc.
OSH
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.41%
2 Consumer Staples 1.28%
3 Industrials 0.73%
4 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
126
Enliven Therapeutics
ELVN
$4.35B
$1.9M 0.04%
210,576
+3,300
+2% +$43.3K
BCEL
127
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.4M 0.03%
462,530
+2,700
+0.6% +$12.6K
NUVB.WS
128
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$253K 0.01%
134,028
– –
ALLK
129
DELISTED
Allakos
ALLK
– –
-305,706
Closed -$32.4M
APLS
130
DELISTED
Apellis Pharmaceuticals
APLS
– –
-26,458
Closed -$872K
ATAI icon
131
AtaiBeckley Inc
ATAI
$2.68B
– –
-317,628
Closed -$4.7M
AVIR icon
132
Atea Pharmaceuticals
AVIR
$402M
– –
-750,307
Closed -$26.3M
BOLT icon
133
Bolt Biotherapeutics
BOLT
$7.67M
– –
-82,462
Closed -$20.9M
INNV icon
134
InnovAge Holding
INNV
$1.48B
– –
-525,000
Closed -$3.47M
KURA icon
135
Kura Oncology
KURA
$874M
– –
-822,500
Closed -$15.4M
MLTX icon
136
MoonLake Immunotherapeutics
MLTX
$1.47B
– –
-154,500
Closed -$1.54M
NUVB icon
137
Nuvation Bio
NUVB
$2.32B
– –
-236,609
Closed -$2.35M
RCKT icon
138
Rocket Pharmaceuticals
RCKT
$397M
– –
-403,270
Closed -$12.1M
TBPH icon
139
Theravance Biopharma
TBPH
$876M
– –
-687,500
Closed -$5.09M
TFX icon
140
Teleflex
TFX
$5.89B
– –
-130,000
Closed -$49M
NEUE
141
DELISTED
NeueHealth
NEUE
– –
-22,063
Closed -$14.4M
GRTX
142
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-568,252
Closed -$4.6M
PRDS
143
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-209,332
Closed -$2.08M
OSH
144
DELISTED
Oak Street Health, Inc.
OSH
– –
-441,000
Closed -$18.8M
EUCRU
145
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
– –
-206,000
Closed -$2.05M
EAR
146
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-48,750
Closed -$6.56M
PHICU
147
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
– –
-201,044
Closed -$2.01M
TMPMU
148
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
– –
-206,000
Closed -$2.05M
TRIL
149
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-628,500
Closed -$11M
2 3 4 5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rock Springs Capital Management held 157 positions worth $4.33B, down 9% from $4.76B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2021 filing shows 4 new, 80 increased, 15 reduced and 21 closed positions. Its largest new stake was Xilio Therapeutics: 85,078 shares worth $19.1M. The largest sale was Teleflex, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2021 buy was Xilio Therapeutics: 85,078 shares worth $19.1M.
  • Rock Springs Capital Management added most to Baxter International in Q4 2021, an estimated $22.8M increase.
  • Rock Springs Capital Management's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Teleflex in Q4 2021, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $4.33B portfolio in Q4 2021.
  • Rock Springs Capital Management opened 4 new positions and closed 21 in Q4 2021.
  • Rock Springs Capital Management's portfolio value fell 9% quarter-over-quarter to $4.33B.

Based on Rock Springs Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.